TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Announced strategic reorganization to focus on in vivo-engineered TCR-T cell therapy for solid tumor
Announced strategic reorganization to focus on in vivo-engineered TCR-T cell therapy for solid tumor